These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3818 related items for PubMed ID: 6795744

  • 1. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
    Korninger C, Collen D.
    Thromb Haemost; 1981 Aug 28; 46(2):561-5. PubMed ID: 6795744
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of epithelial tissue plasminogen activator as a thrombolytic agent in a rabbit model of venous thrombosis.
    Electricwala A, Emeis JJ, Atkinson T.
    J Pharmacol Exp Ther; 1986 Jul 30; 238(1):254-8. PubMed ID: 2425075
    [Abstract] [Full Text] [Related]

  • 11. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D, Stassen JM, Verstraete M.
    J Clin Invest; 1983 Feb 30; 71(2):368-76. PubMed ID: 6681615
    [Abstract] [Full Text] [Related]

  • 12. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV, Barrertt-Bergshoeff M, Hekkenberg RT, Rijken DC.
    Thromb Haemost; 1999 Apr 30; 81(4):605-12. PubMed ID: 10235448
    [Abstract] [Full Text] [Related]

  • 13. Biochemical and biophysical conditions for blood clot lysis.
    Sabovic M, Blinc A.
    Pflugers Arch; 2000 Apr 30; 440(5 Suppl):R134-6. PubMed ID: 11005642
    [Abstract] [Full Text] [Related]

  • 14. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.
    Korninger C, Stassen JM, Collen D.
    Thromb Haemost; 1981 Oct 30; 46(3):658-61. PubMed ID: 7198302
    [Abstract] [Full Text] [Related]

  • 15. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
    Collen D, Stassen JM, Marafino BJ, Builder S, De Cock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J.
    J Pharmacol Exp Ther; 1984 Oct 30; 231(1):146-52. PubMed ID: 6541693
    [Abstract] [Full Text] [Related]

  • 16. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N.
    Thromb Haemost; 1997 Apr 30; 77(4):725-9. PubMed ID: 9134650
    [Abstract] [Full Text] [Related]

  • 17. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
    Hanbücken FW, Schneider J, Günzler WA, Friderichs E, Giertz H, Flohé L.
    Arzneimittelforschung; 1987 Aug 30; 37(8):993-7. PubMed ID: 3118890
    [Abstract] [Full Text] [Related]

  • 18. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N.
    Thromb Haemost; 2001 Apr 30; 85(4):661-6. PubMed ID: 11341502
    [Abstract] [Full Text] [Related]

  • 19. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
    Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, Verstraete M, Collen D, Sobel BE.
    N Engl J Med; 1984 Mar 08; 310(10):609-13. PubMed ID: 6537987
    [Abstract] [Full Text] [Related]

  • 20. Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro.
    Zamarron C, Lijnen HR, Collen D.
    Thromb Res; 1984 Aug 01; 35(3):335-45. PubMed ID: 6431630
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 191.